Patients with type 2 diabetes who have poor blood glucose control are enrolled to evaluate the efficacy and safety of the HbA1c prediction model for adjust the hypoglycemic treatment regimen, compared with the conventional treatment using self-monitoring blood glucose or glycated albumin.

Inclusion Criteria:

• Age ≥18 years old;
• Diagnosed with type 2 diabetes mellitus, and the hypoglycemic treatment was not limited; The study physicians judged that the hypoglycemic treatment regimen was stable in nearly 8 weeks;
• Have HbA1c results within 4 weeks, and the range was 7.5-11%;
• Willing and able to conduct self-glucose monitoring;
• Have not participated in any other research program in the past 4 weeks.

Exclusion Criteria:

• Type 1 diabetes mellitus;
• Severe hypoglycemia ≥1 time or fasting C-peptide ≤0.80 ng/mL in the past 6 months;
• Diabetic ketosis in the last 1 week;
• Oral or inhaled corticosteroids for more than 14 days within the last 8 weeks;
• Anemia, recent blood transfusion, hemoglobinopathy (hemoglobinosis and thalassemia), use of erythropoietic drugs, undergoing dialysis;
• Pregnancy or breastfeeding;
• Receiving chemotherapy or radiation therapy;
• Have a severe mental illness and cannot complete the trial.